Literature DB >> 9231928

Cerebral metastases of cutaneous melanoma.

G Gupta1, A G Robertson, R M MacKie.   

Abstract

Cerebral metastases of cutaneous melanoma carry a very poor prognosis. We report our experience of 31 patients who presented with cerebral metastasis of cutaneous melanoma in a 5-year period between mid-1991 and mid-1996. Cerebral metastases were diagnosed on computerized tomography (CT) scan after patients became symptomatic. The overall median survival in our series was 4 months. Seventeen patients (55%) received treatment with radiotherapy and dexamethasone with resolution of their symptoms, although median survival remained at 4 months. Six patients (19%) had surgery followed by whole brain radiotherapy, with median survival of 5 months. The remaining eight patients received dexamethasone alone. Data from patients surviving less than 2 months and over 6 months suggest that the poor prognostic factors are the presence of more than one cerebral metastasis and additional extracranial metastases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9231928      PMCID: PMC2223930          DOI: 10.1038/bjc.1997.371

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Fotemustine with or without dacarbazine for brain metastases of malignant melanoma.

Authors:  O Merimsky; M Inbar; I Reider-Groswasser; S Chaitchik
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

2.  An evaluation of the management of patients with cerebral metastases from malignant melanoma.

Authors:  J A Gottlieb; E Frei; J K Luce
Journal:  Cancer       Date:  1972-03       Impact factor: 6.860

3.  Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival.

Authors:  M H Amer; M Al-Sarraf; L H Baker; V K Vaitkevicius
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

Review 4.  The radiotherapy of melanoma.

Authors:  C L Harmer
Journal:  Clin Exp Dermatol       Date:  1976-03       Impact factor: 3.470

5.  Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma.

Authors:  G I Stables; V R Doherty; R M MacKie
Journal:  Br J Dermatol       Date:  1992-11       Impact factor: 9.302

6.  Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II.

Authors:  R J Carella; R Gelber; F Hendrickson; H C Berry; J S Cooper
Journal:  Cancer       Date:  1980-02-15       Impact factor: 6.860

7.  A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.

Authors:  J Chang; H Atkinson; R A'Hern; A Lorentzos; M E Gore
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

8.  Cutaneous malignant melanoma, Scotland, 1979-89. The Scottish Melanoma Group.

Authors:  R MacKie; J A Hunter; T C Aitchison; D Hole; K Mclaren; R Rankin; K Blessing; A T Evans; A W Hutcheon; D H Jones
Journal:  Lancet       Date:  1992-04-18       Impact factor: 79.321

9.  Cerebral metastatic melanoma: correlation between clinical and CT findings.

Authors:  O Merimsky; I Reider-Groswasser; M Inbar; F Kovner; S Chaitchik
Journal:  Melanoma Res       Date:  1992-12       Impact factor: 3.599

10.  Role of computed tomography in the staging of patients with local-regional metastases of melanoma.

Authors:  A C Buzaid; L Tinoco; M I Ross; S S Legha; R S Benjamin
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

View more
  17 in total

1.  Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

Authors:  Gautham Gampa; Shruthi Vaidhyanathan; Jann N Sarkaria; William F Elmquist
Journal:  Pharmacol Res       Date:  2017-06-17       Impact factor: 7.658

2.  DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy.

Authors:  Yoshie Umemura; Diane Wang; Kyung K Peck; Jessica Flynn; Zhigang Zhang; Robin Fatovic; Erik S Anderson; Kathryn Beal; Alexander N Shoushtari; Thomas Kaley; Robert J Young
Journal:  J Neurooncol       Date:  2019-12-24       Impact factor: 4.130

3.  Combined razoxane and radiotherapy for melanoma brain metastases. a retrospective analysis.

Authors:  Walter Rhomberg; Helmut Eiter; Franz Boehler; Christoph Saely; Robert Strohal
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

4.  Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.

Authors:  Gautham Gampa; Minjee Kim; Nicholas Cook-Rostie; Janice K Laramy; Jann N Sarkaria; Linda Paradiso; Louis DePalatis; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2018-02-02       Impact factor: 3.922

Review 5.  Melanoma brain metastases: an unmet challenge in the era of active therapy.

Authors:  Vikram Gorantla; John M Kirkwood; Hussein A Tawbi
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 6.  [Malignant melanoma. Diagnosis and therapy].

Authors:  E S Schultz; G Schuler
Journal:  HNO       Date:  2005-11       Impact factor: 1.284

Review 7.  Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.

Authors:  Marc C Chamberlain; Christina S Baik; Vijayakrishna K Gadi; Shailender Bhatia; Laura Q M Chow
Journal:  Neuro Oncol       Date:  2017-01       Impact factor: 12.300

8.  Challenges in the delivery of therapies to melanoma brain metastases.

Authors:  Gautham Gampa; Shruthi Vaidhyanathan; Brynna-Wilken Resman; Karen E Parrish; Svetomir N Markovic; Jann N Sarkaria; William F Elmquist
Journal:  Curr Pharmacol Rep       Date:  2016-11-09

9.  Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control.

Authors:  Amol J Ghia; Jonathan D Tward; Christopher J Anker; Kenneth M Boucher; Randy L Jensen; Dennis C Shrieve
Journal:  J Radiosurg SBRT       Date:  2014

10.  Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.

Authors:  Sofie Wilgenhof; Stephanie Du Four; Hendrik Everaert; Bart Neyns
Journal:  Cancer Invest       Date:  2012-10-08       Impact factor: 2.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.